Breaking News

FAR Biotech, Aragen Life Sciences Partner to Advance Neurodegeneration Candidates

Aragen will provide IDD services to support FAR Biotech's AI-driven, quantum biomodelling approach.

Aragen Life Sciences (Aragen), a contract research and development organization (CRO), and FAR Biotech (FAR), a U.S.-based, AI-driven, computational drug discovery company, have collaborated to advance preclinical programs in neurodegeneration. As part of the collaboration, Aragen will deploy its discovery platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration. “We look forward to initiating our collaboration with FAR Biotech to advan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters